Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Inflammation

NSAIDs and cardiovascular risk in arthritis

Nature Reviews Cardiology volume 14, pages 69–70 (2017)Cite this article

Subjects

In the PRECISION trial involving patients with arthritis, moderate doses of a selective cyclooxygenase 2 inhibitor were not associated with increased cardiovascular events compared with submaximal doses of nonselective NSAIDs. The balance between pain relief and cardiovascular risk with NSAIDs should be further investigated in patients with chronic inflammatory rheumatic diseases.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. U.S. Department of Health & Human Services. FDA public health advisory: safety of Vioxx. FDA http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106274.htm (2004).

  2. Nissen, S. E. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1611593 (2016).

  3. Castañeda, S., Nurmohamed, M. T. & González-Gay, M. A. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 30, 851–869 (2016).

    Article  Google Scholar 

  4. López-Mejias, R. et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun. Rev. 15, 1013–1030 (2016).

    Article  Google Scholar 

  5. Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 76, 17–28 (2017).

    Article  CAS  Google Scholar 

  6. Martín-Martínez, M. A. et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin. Arthritis Rheum. 44, 1–8 (2014).

    Article  Google Scholar 

  7. Kroon, F. P. B. et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD010952 http://dx.doi.org/10.1002/14651858.CD010952.pub2 (2015).

  8. Lindhardsen, J. et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann. Rheum. Dis. 73, 1515–1521 (2014).

    Article  CAS  Google Scholar 

  9. Goodson, N. J. et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann. Rheum. Dis. 68, 367–372 (2009).

    Article  CAS  Google Scholar 

  10. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071–1080 (2005).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.A.G.-G.'s work is supported by 'Fondo de Investigación Sanitaria' (grants PI06/0024, PS09/00748, PI12/00060, and PI15/00525) from 'Instituto de Salud Carlos III' (ISCIII, Health Ministry, Spain), and is partially supported by RETICS Program RD12/0009 (RIER) from ISCIII.

Author information

Authors and Affiliations

  1. Rheumatology Division, Miguel A. González-Gay is at the University of Cantabria, School of Medicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Hospital Universitario Marqués de Valdecilla, Avenida de Valdecilla, s/n, 39008, Santander, Spain.,

    Miguel A. González-Gay

  2. Cardiology Division, Carlos González-Juanatey is at the Hospital Universitario Lucus Augusti, c/ Ulises Romero 1, Lugo 27003, Spain.,

    Carlos González-Juanatey

Authors
  1. Miguel A. González-Gay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos González-Juanatey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miguel A. González-Gay.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

González-Gay, M., González-Juanatey, C. NSAIDs and cardiovascular risk in arthritis. Nat Rev Cardiol 14, 69–70 (2017). https://doi.org/10.1038/nrcardio.2016.208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2016.208

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing